Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate [3]

Leukemia

Volumn 20, Issue 6, 2006, Pages 1162-1164

  Ohnishi, K ^a   Sakai, F ^b   Kudoh, S ^c   Ohno, R ^d  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; BUSULFAN; CORTICOSTEROID; HYDROXYUREA; IMATINIB; RANIMUSTINE;

ADULT; AGED; BRONCHIECTASIS; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSPNEA; EOSINOPHILIA; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYPOXIA; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LETTER; LUNG CARCINOMA; LUNG FIBROSIS; MALE; ORGANIZING PNEUMONIA; PRIORITY JOURNAL; THORAX RADIOGRAPHY;

EID: 33744467685     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404207     Document Type: Letter

References (8)

1. Druker BJ, Talpaz M, Resta D, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
2. Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC. Pulmonary drug toxicity: Radiologic and pathologic manifestations. Radiographics 2000; 20: 1245-1259.
3. Sakai F, Noma S, Kurihara Y, Yamada H, Azuma A, Kudoh S et al. Leflunomide-related ILD: Imaging features. Modern Rheumatol, in press.
4. Bergeron A, Bergot E, Vilela G, Ades L, Devergie A, Esperou H et al. Hypersensitivity pneumonitis related to imatinib mesylate. J Clin Oncol 2002; 20: 4271-4272.
5. Rosado MF, Donna E, Ahn YS. Challenging problems in advanced malignancy: case 3. Imatinib mesylate-induced interstitial pneumonitis. J Clin Oncol 2003; 78: 3171-3173.
6. Ma CX, Hobday TJ, Jett JR. Imatinib mesylate-induced interstitial pneumonitis. Mayo Clin Proc 2003; 78: 1578-1579.
7. Yokoyama T, Miyazawa K, Kurakawa E, Nagate A, Shimamoto T, Iwaya K et al. Interstitial pneumonia induced by imatinib mesylate: Pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration. Leukemia 2004; 18: 645-646.
8. Isshiki I, Yamaguchi K, Okamoto S. Interstitial pneumonitis during imatinib therapy. Br J Haematol 2004; 125: 420.